King Drug Co. of Florence, Inc. v. Cephalon, Inc.
309 F.R.D. 195
E.D. Pa.2015Background
- Cephalon marketed Provigil (modafinil) under patents extending exclusivity to April 6, 2015; four generics (Teva, Ranbaxy, Mylan, Barr) filed ANDAs in 2002 and litigated infringement.
- Between December 2005 and February 2006 Cephalon settled with each generic via reverse-payment (pay-for-delay) settlements setting ``date-certain'' launches before patent expiry and contingent-launch provisions; Cephalon paid about $300 million total.
- Direct-purchaser class (22 wholesalers) sued under antitrust theories (Actavis rule-of-reason challenge to reverse payments) claiming overcharges from delayed generic entry (class period June 24, 2006–Aug 31, 2012).
- Plaintiffs relied on economist Jeffrey Leitzinger to provide class-wide proof of antitrust impact and aggregate damages (two models: contemporaneous estimates and backcast from 2012 real-world entry); defendants offered competing expert testimony (Ordover) emphasizing individualized issues like generic bypass.
- Court analyzed Rule 23 requirements — numerosity (22 members), commonality, typicality, adequacy, predominance (impact and damages), and superiority — and granted certification under Rule 23(b)(3).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Numerosity — joinder practicability | Class has 22 members, geographically dispersed; joinder impracticable; judicial economy favors class | Fewer than 40 members invites scrutiny; some disputed members shouldn’t count (assignments, no pre-entry purchases) | Court included disputed members (Meijer, SAJ, King Drug, Droguería) and found 22 members; joinder impracticable given dispersion, case complexity, and some small claims |
| Commonality/Typicality/Adequacy | Liability elements (existence of reverse payments, monopoly power, justification) are common; named plaintiffs typical; counsel adequate | Defendants mainly contested adequacy via generic bypass conflict | Commonality, typicality, and adequacy satisfied; generic bypass does not create an adequacy conflict under Third Circuit precedent |
| Predominance — antitrust impact | Impact is provable class-wide via Leitzinger: historical studies, defendants’ internal analyses, and 2012 real-world data show price drop and substitution | Generic bypass and summary-judgment ruling on overall conspiracy produce individualized causation and damages inquiries that defeat predominance | Impact can be proven with common evidence; K-Dur and Hanover Shoe reject requiring lost-profits proof or passing-on defense; standing/causation concerns (Mid-West Paper) distinguished — predominance on impact met |
| Predominance — damages | Aggregate damages reliably measurable with class-wide models (including models accounting for varying numbers of entrants and class-wide adjustment for bypass) | Comcast requires damages model to fit liability theory and be classwide; summary-judgment on overall conspiracy breaks the model (need bilateral attribution) | Court finds Leitzinger’s models consistent with liability theory (accounts for 2–5 entrants and alternative scenarios; subtracts bypass class-wide); Comcast distinguished — predominance on damages met |
| Superiority | Class adjudication achieves economies, uniformity, and enables smaller claimants to vindicate rights | Small number of sophisticated entities and concentration of claims among “Big Three” make joinder/individual suits feasible | Class action is superior given complexity, extensive discovery, geographic dispersion, and potential inefficiency of multiple suits |
Key Cases Cited
- Wal-Mart Stores v. Dukes, 131 S. Ct. 2541 (2011) (commonality standard; central common contention capable of classwide resolution)
- In re Hydrogen Peroxide Antitrust Litig., 552 F.3d 305 (3d Cir. 2008) (rigorous Rule 23 analysis; weighing expert testimony at certification)
- FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013) (reverse-payment settlements evaluated under the rule of reason)
- Hanover Shoe, Inc. v. United Shoe Mach. Corp., 392 U.S. 481 (1968) (rejecting passing-on defense; overcharge as antitrust injury)
- In re K-Dur Antitrust Litig., 686 F.3d 197 (3d Cir. 2012) (direct purchasers need not prove lost profits; overcharge standing; generic bypass does not negate injury)
- Comcast Corp. v. Behrend, 133 S. Ct. 1426 (2013) (damages model must be consistent with the theory of liability for Rule 23(b)(3) predominance)
- Amgen Inc. v. Connecticut Retirement Plans & Trust Funds, 133 S. Ct. 1184 (2013) (individual questions need not be absent for predominance)
- Mid-West Paper Prods. Co. v. Continental Group, 596 F.2d 573 (3d Cir. 1979) (standing/causation limits where plaintiff purchased only from non-defendants)
- Dewey v. Volkswagen Aktiengesellschaft, 681 F.3d 170 (3d Cir. 2012) (conflict-of-interest concerns in class representation; distinguishable facts)